Curated News
By: NewsRamp Editorial Staff
July 02, 2025
Tonix Pharmaceuticals Advances Cancer Treatment with mTNX-1700 Breakthrough
TLDR
- Tonix Pharmaceuticals' TNX-1700 offers a competitive edge in cancer treatment by enhancing immunotherapy effectiveness and reducing metastases in gastric cancer models.
- Tonix Pharmaceuticals developed mTNX-1700 in collaboration with Columbia University, combining murine trefoil factor-2 and serum albumin to improve anti-PD-1 immunotherapy outcomes.
- The development of TNX-1700 by Tonix Pharmaceuticals represents a significant step forward in making cancer treatments more effective and improving patient survival rates.
- Tonix Pharmaceuticals' innovative approach with TNX-1700 could revolutionize cancer treatment by overcoming checkpoint resistance in solid tumors.
Impact - Why it Matters
This news is crucial as it showcases a potential breakthrough in cancer treatment, specifically for gastric and colorectal cancers, which are among the leading causes of cancer deaths worldwide. The development of TNX-1700 could significantly improve the efficacy of immunotherapy, offering new hope to patients with solid tumors resistant to current treatments. Furthermore, Tonix Pharmaceuticals' broader research and development efforts in pain management and public health challenges underscore the company's commitment to addressing some of the most pressing medical needs today.
Summary
Tonix Pharmaceuticals (NASDAQ: TNXP), in collaboration with Columbia University Medical School, has made significant strides in cancer research with its fusion protein candidate mTNX-1700. Preclinical findings published in Cancer Cell demonstrate that mTNX-1700 not only increased survival rates but also reduced metastases in mouse models of gastric cancer. This breakthrough highlights the potential of mTNX-1700 to enhance anti-PD-1 immunotherapy by targeting immunosuppressive neutrophils and inhibiting cancer-driven granulopoiesis. The human counterpart, TNX-1700, is currently under development for treating gastric and colorectal cancers, offering hope for overcoming checkpoint resistance in solid tumors. Dr. Seth Lederman, CEO of Tonix Pharmaceuticals, emphasized the importance of these findings for the future of cancer treatment.
Tonix Pharmaceuticals is not just focused on cancer research; it is also a leader in addressing public health challenges and pain management. The company is preparing to submit a New Drug Application for TNX-102 SL, aimed at managing fibromyalgia, following successful phase 3 studies. Additionally, Tonix is developing TNX-4200 under a contract with the U.S. Department of Defense, targeting biological threats to military personnel. With a robust portfolio that includes treatments for CNS disorders, rare diseases, and infectious diseases, Tonix Pharmaceuticals is at the forefront of biopharmaceutical innovation. For more details on their groundbreaking work, visit www.TonixPharma.com.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Tonix Pharmaceuticals Advances Cancer Treatment with mTNX-1700 Breakthrough
